Online inquiry

IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9039MR)

This product GTTS-WQ9039MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FLT1 gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001159920.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2321
UniProt ID P17948
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9039MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15624MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ2162MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ8886MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3747MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ2193MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ4246MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ13055MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ10221MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW